AACR Annual Meeting 2020

AACR Annual Meeting 2020 April 24-29, 2020 / San Diego / USA Madiha Derouazi attending

ESMO Immuno-Oncology Congress 2019

ESMO Immuno-Oncology Congress 2019 December 11–14, 2019 / Geneva / Switzerland AMAL Team attending

BIO-Europe 2019

BIO-Europe 2019 November 11–13, 2019 / Hamburg / Germany Laurence de Schoulepnikoff attending

Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform

Boehringer Ingelheim today announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and advancing first-in-class therapeutic cancer vaccines derived from its technology platform KISIMA.

AMAL Therapeutics enters clinical collaboration with Boehringer Ingelheim to evaluate ATP128 in combination with BI754091

Geneva, Switzerland – 02 May 2019 – AMAL Therapeutics (AMAL), a Swiss biotech developing novel, peptide-based therapeutic cancer vaccines, today announces that it has entered into a collaborative agreement with Boehringer Ingelheim. AMAL will conduct an international Phase Ib clinical study, referred to as KISIMA-01, to evaluate the combination of its lead candidate, ATP128,with Boehringer […]

Amal Therapeutics to publish R&D outcomes in JCI Insight

Geneva, Switzerland, April 24, 2019 – Amal Therapeutics announced today that part of its recent research findings about its self-adjuvanted chimeric protein vaccin platform, named KISIMA™, is on line on the JCI Insight website on Wednesday April 24. This publication describe the KISIMA™ efficacy in several murine tumor models (with model-, neo- and self-antigens),  its […]

AMAL Therapeutics and Natera to Partner on Clinical Trial Using Signatera MRD Test to Assess Treatment Response to Colorectal Cancer Vaccine

Natera, Inc., a global leader in cell-free DNA testing, will partner with AMAL Therapeutics on a clinical trial focused on stage IV colorectal cancer. This study adds to the growing number of pharmaceutical trials using Natera’s SignateraTM molecular residual disease (MRD) assay as a biomarker to assess treatment response. View PDF  

CICON 2019

CICON 2019 Sept. 25 – 28, 2019 / Paris / France Elodie Belnoue attending

BIO International Convention 2019

BIO International Convention 2019 June 3 – 6, 2019 / Philadelphia / USA Madiha Derouazi and Laurence de Schoulepnikoff attending

CIMT Annual Meeting 2019

CIMT Annual Meeting 2019 May 21 – 23, 2019 / Mainz / Germany Matteo Rossi attending